Myers CE - Search Results

1

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.

Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. Dawson NA, et al. Among authors: myers ce. J Clin Oncol. 1997 Apr;15(4):1470-7. doi: 10.1200/JCO.1997.15.4.1470. J Clin Oncol. 1997. PMID: 9193342 Clinical Trial.

2

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Among authors: myers ce. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.

3

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.

Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Bitton RJ, et al. Among authors: myers ce. J Clin Oncol. 1995 Sep;13(9):2223-9. doi: 10.1200/JCO.1995.13.9.2223. J Clin Oncol. 1995. PMID: 7666080 Clinical Trial.

4

Suramin decreases circulating levels of insulin-like growth factor-I.

Sartor O, Cooper MR, Khleif SN, Myers CE. Sartor O, et al. Among authors: myers ce. Am J Med. 1994 Apr;96(4):390. doi: 10.1016/0002-9343(94)90073-6. Am J Med. 1994. PMID: 8166161 No abstract available.

5

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.

Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Dawson NA, et al. Among authors: myers ce. Cancer. 1995 Aug 1;76(3):453-62. doi: 10.1002/1097-0142(19950801)76:3<453::aid-cncr2820760316>3.0.co;2-e. Cancer. 1995. PMID: 8625127 Clinical Trial.

6

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.

Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. Bowden CJ, et al. Among authors: myers ce. Cancer Chemother Pharmacol. 1996;39(1-2):1-8. doi: 10.1007/s002800050531. Cancer Chemother Pharmacol. 1996. PMID: 8995493 Clinical Trial.

7

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.

Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D. Thibault A, et al. Among authors: myers ce. Tumori. 1998 Jan-Feb;84(1):87-9. doi: 10.1177/030089169808400120. Tumori. 1998. PMID: 9619724 Clinical Trial.

8

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV. Bergan RC, et al. Among authors: myers ce. Clin Cancer Res. 1999 Sep;5(9):2366-73. Clin Cancer Res. 1999. PMID: 10499606 Clinical Trial.

9

Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.

Sartor O, McLellan CA, Myers CE, Borner MM. Sartor O, et al. Among authors: myers ce. J Clin Invest. 1992 Dec;90(6):2166-74. doi: 10.1172/JCI116102. J Clin Invest. 1992. PMID: 1281826 Free PMC article.

10

A pilot study of suramin in the treatment of progressive refractory follicular lymphomas.

La Rocca RV, Cooper MR, Stein CA, Kohler D, Uhrich M, Weinberger E, Myers CE. La Rocca RV, et al. Among authors: myers ce. Ann Oncol. 1992 Jul;3(7):571-3. Ann Oncol. 1992. PMID: 1498080 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

437 results

Search Page

Filters